OBJECTIVE: This study validated a brief measure of fatigue in rheumatoid arthritis (RA), the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. METHODS: The FACIT Fatigue was tested along with measures previously validated in RA: the Multidimensional Assessment of Fatigue (MAF) and Medical Outcomes Study Short-Form 36 (SF-36) Vitality. The sample included 636 patients with RA enrolled in a 24 week double blind, randomized clinical trial (RCT) ofadalimumab versus placebo. RESULTS: The FACIT Fatigue showed good internal consistency (alpha = 0.86 to 0.87), strong association with SF-36 Vitality (r = 0.73 to 0.84) and MAF (r = -0.84 to -0.88), and the ability to differentiate patients according to clinical change using the American College of Rheumatology (ACR) response criteria (ACR 20/50/70). Psychometric performance of the FACIT Fatigue scale was comparable to that of the other 2 fatigue measures. A minimally important difference in FACIT Fatigue change score of 3-4 points was confirmed in a separate sample of 271 patients with RA enrolled in a second double blind RCT of adalimumab versus placebo. CONCLUSION: The FACIT Fatigue is a brief, valid measure for monitoring this important symptom and its effects on patients with RA.
RCT Entities:
OBJECTIVE: This study validated a brief measure of fatigue in rheumatoid arthritis (RA), the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. METHODS: The FACIT Fatigue was tested along with measures previously validated in RA: the Multidimensional Assessment of Fatigue (MAF) and Medical Outcomes Study Short-Form 36 (SF-36) Vitality. The sample included 636 patients with RA enrolled in a 24 week double blind, randomized clinical trial (RCT) of adalimumab versus placebo. RESULTS: The FACIT Fatigue showed good internal consistency (alpha = 0.86 to 0.87), strong association with SF-36 Vitality (r = 0.73 to 0.84) and MAF (r = -0.84 to -0.88), and the ability to differentiate patients according to clinical change using the American College of Rheumatology (ACR) response criteria (ACR 20/50/70). Psychometric performance of the FACIT Fatigue scale was comparable to that of the other 2 fatigue measures. A minimally important difference in FACIT Fatigue change score of 3-4 points was confirmed in a separate sample of 271 patients with RA enrolled in a second double blind RCT of adalimumab versus placebo. CONCLUSION: The FACIT Fatigue is a brief, valid measure for monitoring this important symptom and its effects on patients with RA.
Authors: Jin-Shei Lai; David Cella; Seung Choi; Doerte U Junghaenel; Christopher Christodoulou; Richard Gershon; Arthur Stone Journal: Arch Phys Med Rehabil Date: 2011-10 Impact factor: 3.966
Authors: Amanda L Lusa; Isabelle Amigues; Henry R Kramer; Thuy-Tien Dam; Jon T Giles Journal: Arthritis Care Res (Hoboken) Date: 2015-01 Impact factor: 4.794
Authors: Rebecca A Campo; Neeraj Agarwal; Paul C LaStayo; Kathleen O'Connor; Lisa Pappas; Kenneth M Boucher; Jerry Gardner; Sierra Smith; Kathleen C Light; Anita Y Kinney Journal: J Cancer Surviv Date: 2013-10-30 Impact factor: 4.442
Authors: Manjit K Singh; Philip J Clements; Daniel E Furst; Paul Maranian; Dinesh Khanna Journal: Arthritis Care Res (Hoboken) Date: 2012-02 Impact factor: 4.794
Authors: Neli Muraki Ishikawa; Luiz Claudio Santos Thuler; Alessandra Grasso Giglio; Clarissa Seródio da Rocha Baldotto; Carlos José Coelho de Andrade; Sophie Françoise Mauricette Derchain Journal: Support Care Cancer Date: 2009-07-23 Impact factor: 3.603